The best night of the year at #summerlark raising funds and awareness for our cancer patient support program! Thank you Barenaked Ladies for an amazing show!

Some fun #Summerlark24 selfies with Katherine Ansley, MD #BethFisher #KatieDuckworth at Barenaked Ladies concert supporting Atrium Health Wake Forest Baptist Wake Forest Baptist - Comprehensive Cancer Center Patient Support Program Levine Cancer @AtriumHealth

Agree! Really looking forward to it! Such an important cause!

Exciting that a new option is on the horizon. Magnitude of benefit, patient reported outcomes, adverse-events, and understanding the role (if any) of HER2-low as a biomarker will shape the place T-DXd ultimately takes for HR+ HER2-low or ultralow MBC in the lineup.
#DB06 #bcsm

The NATALEE phase 3 trial of adjuvant ribo for stage II-III HR+ BC is published in NEJM. With 28 months f-up, adding ribo for 3y to adjuvant AI led to a significant benefit in 3y iDFS (Δ≃3%). Updated results at SABCS23 were consistent with this analysis. nejm.org/doi/full/10.10…

Giving a breast oncologist perspective on this debate.

1) Estrogen-only HRT is not linked to a higher risk of breast cancer (BC) in pts with no BC history. Cite: Women’s Health Initiative

2) HRT DID increase risk of recurrence in BC survivors. Cite HABITS trial.

☀️The Breast Cancer Session featuring #AntibodyDrugConjugates stole the morning show at the scientific conference Sarah Cannon Docs #SCRI
⭐️Drs. Erika Hamilton, MD, Joyce O'Shaughnessy, Denise Yardley led an impactful discussion on ADC drug development, with a spotlight on…

This was our goal Wake Forest Baptist - Comprehensive Cancer Center Lexington satellite clinic. Quality care closer to home: “It is about building relationships, understanding each patient's story, and providing care that encompasses not just their physical health but their emotional and social well-being.”

Important update of the ABC trials. With 6.9y of follow up, adjuvant AC-T had a small RFI benefit over TC, restricted to triple-negative tumors. No OS benefit by adding anthracyclines, but a major increase in leukemias (7 vs 1) & non-BC deaths (62 vs 34). ascopubs.org/doi/10.1200/JC…

Thank you Dr. Mesa for representing our team so well 👏

Breast cancer incidence rates among women aged 20-49 is increasing, driven by increases in ER+ tumors. Prevention efforts in young women need to adopt a targeted approach to address racial disparities in incidence rates. ja.ma/3OnyiMA

The highly debated results of PALOMA2 now published on JCO: the addition of palbociclib to 1L letrozole did not improve OS in HR+ MBC. The reason for the discrepancy with ribo & abema data remains unclear. Ultimately led to a reduction in the use of palbo.
ascopubs.org/doi/10.1200/JC…

ALTERNATE trial: 1300 patients with stage II-III HR+/HER2- breast cancer randomized to neoadjuvant fulvestrant, AI, or both in combo. Low rate of pCR at surgery (0.5-1.2%) and similar mPEPI 0 rate irrespective of study arm.
jamanetwork.com/journals/jamao…

2023 was an outstanding year for breast cancer research
As we start wrapping up #SABCS23 , we need to think about how to incorporate what we learned in the clinic and future research.
Looking forward to what is yet to come to improve outcomes for our patients!
OncoAlert #BCSM

INAVO120: Fulv + palbo +/- inavolisib in HR+ MBC w/relapse on or w/i 1 yr of adj ET --> impressive data

PFS: 15.0 vs 7.2 mo HR 0.43 , p<0.0001
OS trend HR 0.64
58.6% hyperglycemia (5.6% g3-4)
51.2% stomatitis (5.6% g3-4)
25.3% rash (g3-4)

Komal Jhaveri OncoAlert #SABCS23

Have been looking forward to this data on INAVO120 after serving as the local PI for this trial Wake Forest Baptist - Comprehensive Cancer Center. Happy to see the data today supports what we saw in clinic to overcome endocrine resistance with improved PFS with triplet therapy in PIK3CA mutated BC #SABCS23

ECOG ACRIN E 4112using 12 gene DCIS score

▪️About 50% with low DCIS score

🔺Low score and no ☢️ 5.1% ipsilateral recurrence compared to 4.5% w/ high score and ☢️

👍🏼appears we may be able to select good prognosis pts and omit XRT for small DCIS

#SABCS23 SABCS

Dr. Hortobagyi presents NATALEE final iDFS benefit 3.1% with ribo 400 mg for 3 years. Risk of invasive dz ⬇️ 25% but audience questions how many pts have to be treated to prevent 1 recurrence at such high cost #SABCS23

Published synchronously in JAMA Pregnancy After Breast Cancer in Young BRCA Carriers jamanetwork.com/journals/jama/… SABCS Matteo Lambertini, MD PhD OncoAlert #SABCS23

Published synchronously with #SABCS23 Reshma Jagsi Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology SABCS OncoAlert